CN104721157A - Epsiprantel-containing pet tablet and preparation method thereof - Google Patents
Epsiprantel-containing pet tablet and preparation method thereof Download PDFInfo
- Publication number
- CN104721157A CN104721157A CN201310707249.1A CN201310707249A CN104721157A CN 104721157 A CN104721157 A CN 104721157A CN 201310707249 A CN201310707249 A CN 201310707249A CN 104721157 A CN104721157 A CN 104721157A
- Authority
- CN
- China
- Prior art keywords
- epsiprantel
- tablet
- agent
- tablet containing
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to veterinary medicine and preparing method technical field, and in particular relates to an epsiprantel-containing pet tablet and a preparation method thereof, the tablet preparation comprises (a) epsiprantel as a raw material medicine, (b) an adhesive, (c) a wetting agent, (d) a disintegrating agent, (e) a filler and (f) a sweetener. The epsiprantel-containing pet tablet is prepared by a wet process, and is a white-like tablet in character. The epsiprantel-containing pet tablet is good in stability and good in palatability, and can be used as a veterinary oral preparation.
Description
Technical field
The invention belongs to analgesia for animals and preparation method technical field, be specifically related to a kind of preparation method of epsiprantel tablet.
Technical background
Epsiprantel is white crystals, odorless, bitter in the mouth.Dog tapeworm (Diphlidium xaninum) also claims " diphlidium caninum ".Nang Gong cestode section.The long 100-400 millimeter of body, nodal plate about 120 altogether, microscler, the widest about 3 millimeters.Cephalomere is little, slightly assumes diamond in shape, and has the rostellum of clavate, the little hook of raw 3 ~ 4 row of ring.The light red band of body colour is yellow.Colonize in the little enteral of the beasts of prey such as dog, cat, Vulpes, during severe infections, cause the symptom such as intestinal obstruction, anemia.Intermediate host is dog flea, dog louse etc.People also can be infected, but rare.Be same kind with taeniasis suis, individual variation is larger.
Epsiprantel is utilized wet preparation method by prominent features of the present invention exactly, is prepared into oral tablet for animals.The epsiprantel tablet stability prepared by this method is good, good palatability, the assimilation effect that tool is good, for China's veterinary clinic utilizes epsiprantel to provide a kind of new preparation better.
Summary of the invention
The object of the invention is to develop a kind of epsiprantel oral tablet, heighten the effect of a treatment, improve stability and the palatability of medicine, tool long-acting.
The present invention, for achieving the above object, provides a kind of water tablet containing epsiprantel, it is characterized in that preparation specifically consists of:
(a) epsiprantel crude drug 5-20% (W/W);
(b) binding agent 10-30% (W/W);
(c) wetting agent 5-20% (W/W);
(d) disintegrating agent 20-50% (W/W);
(e) filler 20-30% (W/W);
(f) sweeting agent 2-3% (W/W);
Described a kind of tablet containing epsiprantel, it is characterized in that disintegrating agent be selected from replace hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl starch sodium, PVPP, cCMC-Na, cross-linked carboxymethyl cellulose are received, cross linked polyvinyl pyrrolidone, microcrystalline Cellulose one or more;
The tablet of described a kind of epsiprantel, it is characterized in that described filler be selected from lactose, amylum pregelatinisatum, dextrin, microcrystalline Cellulose one or more.
Described a kind of tablet containing epsiprantel, it is characterized in that described binding agent be selected from polyvidone (PVP), HPMC, PVP, methylcellulose, sodium carboxymethyl cellulose one or more.
Described a kind of tablet containing epsiprantel, it is characterized in that described lubricant be selected from magnesium stearate, micropowder silica gel, talcous one or more.
Described a kind of tablet containing epsiprantel, is characterized in that one or more that described sweeting agent is selected from aspartame, stevioside, protein sugar.
Described a kind of tablet containing epsiprantel, when it is characterized in that granulating, the granularity of granule should control at 30 orders once.
Described a kind of tablet containing epsiprantel, is characterized in that preparation method is as follows:
Measure all stock and adjuncts according to prescription, cross 30-120 mesh sieve; Wherein disintegrating agent and filler respectively in add and Extra Section, the ratio 1-4:1 of Nei Jia and Extra Section, weight ratio; Inside add and weigh respectively with Extra Section, and carry out labelling; By epsiprantel raw material and all in add adjuvant and put mix homogeneously in mixer altogether; Add binding agent, continue mixing, make soft material, 30 mesh sieves are granulated; By granule after 50 ° of C-55 ° of C are dried, 30 mesh sieve granulate.
Detailed description of the invention
Be explained the present invention with example below, but example does not limit the scope of the invention, scope of the present invention and core content are determined according to claims.
Example: 10% epsiprantel water tablet
[prescription] epsiprantel 5+10% (W/W)
Microcrystalline Cellulose 20% (W/W)
PVP 15% (W/W)
Lactose 30% (W/W)
Aluminium stearate 10% (W/W)
Aspartame 15% (W/W)
[preparation]
Get prescription and measure epsiprantel and above-mentioned various adjuvant is prepared according to aforementioned preparation process, be i.e. obtained epsiprantel water tablet.
Claims (7)
1., containing a tablet for epsiprantel, it is characterized in that preparation specifically consists of:
(a) epsiprantel crude drug 5-20% (W/W);
(b) binding agent 10-30% (W/W);
(c) wetting agent 5-20% (W/W);
(d) disintegrating agent 20-50% (W/W);
(e) filler 20-30% (W/W);
(f) sweeting agent 2-3% (W/W).
2. by a kind of tablet containing epsiprantel according to claim 1, it is characterized in that disintegrating agent be selected from replace hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl starch sodium, PVPP, cCMC-Na, cross-linked carboxymethyl cellulose are received, cross linked polyvinyl pyrrolidone, microcrystalline Cellulose one or more.
3. by the tablet of a kind of epsiprantel according to claim 1, it is characterized in that described filler be selected from lactose, amylum pregelatinisatum, dextrin, microcrystalline Cellulose one or more.
4. by a kind of tablet containing epsiprantel according to claim 1, it is characterized in that described binding agent be selected from polyvidone (PVP), HPMC, PVP, methylcellulose, sodium carboxymethyl cellulose one or more.
5. by a kind of tablet containing epsiprantel according to claim 1, it is characterized in that described lubricant be selected from magnesium stearate, micropowder silica gel, talcous one or more.
6., by a kind of tablet containing epsiprantel according to claim 1, it is characterized in that one or more that described sweeting agent is selected from aspartame, stevioside, protein sugar.
7., by a kind of tablet containing epsiprantel according to claim 1, when it is characterized in that granulating, the granularity of granule should control at 30 orders once.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310707249.1A CN104721157A (en) | 2013-12-20 | 2013-12-20 | Epsiprantel-containing pet tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310707249.1A CN104721157A (en) | 2013-12-20 | 2013-12-20 | Epsiprantel-containing pet tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104721157A true CN104721157A (en) | 2015-06-24 |
Family
ID=53445959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310707249.1A Pending CN104721157A (en) | 2013-12-20 | 2013-12-20 | Epsiprantel-containing pet tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104721157A (en) |
-
2013
- 2013-12-20 CN CN201310707249.1A patent/CN104721157A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524333B (en) | Amoxicillin dispersible tablet and production method thereof | |
| CN101756906B (en) | Pharmaceutical composition of cefcapene pivoxil hydrochloride granules and preparation method thereof | |
| CN101401810A (en) | Dispersible tablet containing Cefixime and preparation method thereof | |
| CN103142494A (en) | Ornidazole oral preparation and preparation method thereof | |
| CN103751201A (en) | Anti-parasitic orally disintegrating tablet for dogs and cats and preparation method thereof | |
| CN104337822A (en) | Compound tablets containing mebendazole and dipterex and used for deworming on pets, and preparation method thereof | |
| CN104721157A (en) | Epsiprantel-containing pet tablet and preparation method thereof | |
| CN102948418A (en) | Tea saponin tablet and preparation method thereof | |
| CN101269014B (en) | Orally disintegrating tablet of risperidone and preparation method thereof | |
| CN101011362A (en) | Dispersible tablet of pidotimod and its preparing process and use | |
| CN104337776A (en) | Tablets containing diclofenac sodium and having analgesic effect on pets, and preparation method thereof | |
| CN104338113A (en) | Amfomycin calcium + hydrocortisone + kanamycin sulfate compound tablet for infection prevention of pets, and its preparation method | |
| CN102100674A (en) | Febantel chewable tablets for dogs and cats | |
| CN104274415A (en) | Atipamezole hydrochloride-containing calming and pain easing tablet for pets, and preparation method thereof | |
| CN104337777A (en) | Tablets containing ketoprofen and having analgesic effect on pets, and preparation method thereof | |
| CN104069085A (en) | Aspirin enteric sustained-release capsule and preparation method thereof | |
| CN104721216A (en) | Decoquinate and lincomycin hydrochloride-containing pet insect repellent tablet and preparation method thereof | |
| CN104337815A (en) | Zolazepam hydrochloride and tiletamine hydrochloride-containing compound tablet for easing pains of pets, and its preparation method | |
| CN104274475A (en) | Gentamicin sulfate and betamethasone valerate containing compound tablet for treating skin infection of dogs | |
| CN103877092A (en) | Compound niclosamide chewing tablet used for dogs and cats | |
| CN104721214A (en) | Lincomycin hydrochloride and pyrantel tartrate-containing compound pet tablet and preparation method thereof | |
| CN112438968A (en) | Compound maleic acid dextro-bromopheniramine solid preparation and preparation method thereof | |
| CN101352440A (en) | Guaifenesin, pseudoephedrine hydrochloride and dextromethorphan hydrobromide sustained-release preparation and preparation method thereof | |
| CN101249080A (en) | Acetylkitasamycin dispersible tablet and method of preparing the same | |
| TW200633646A (en) | Process for preparing granules of hydrophilic active principle by extrusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150624 |
|
| WD01 | Invention patent application deemed withdrawn after publication |